phenyl acetate has been researched along with cp 544326 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almaden, C; Anderson, S; Carreiro, S; Dinh, D; Fortner, J; Gale, D; Gukasyan, H; Krauss, A; Lafontaine, J; Niesman, M; Prasanna, G; Sartnurak, S; Toris, C; Wells, P; Xiang, C; Younis, H | 1 |
| Courtney, R; Raber, S; Schachar, RA; Zhang, M | 1 |
| Benetz, BA; Howell, SJ; Lass, JH; Raber, S; Schachar, RA; Szczotka-Flynn, LB; Thomas, KV; Zhang, M | 1 |
| Affolter, T; Eighmy, JJ; Evans, MG; Jessen, BA; Khoh-Reiter, S; Lee, D; Miller, PE; Shiue, MH; Trajkovic, D; Yanochko, GM | 1 |
| Banik, A; Chen, D; Dingledine, R; Flood, K; Ganesh, T; Rojas, A | 1 |
2 trial(s) available for phenyl acetate and cp 544326
| Article | Year |
|---|---|
A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Prostaglandins F, Synthetic; Receptors, Prostaglandin E, EP2 Subtype; Sulfonamides; Treatment Outcome | 2011 |
Subclinical increased anterior stromal reflectivity with topical taprenepag isopropyl.
Topics: Acetates; Administration, Topical; Aged; Aged, 80 and over; Cell Count; Corneal Diseases; Corneal Keratocytes; Corneal Pachymetry; Corneal Stroma; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Endothelium, Corneal; Epithelium, Corneal; Glaucoma, Open-Angle; Humans; Latanoprost; Microscopy, Confocal; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; Receptors, Prostaglandin E, EP2 Subtype; Refraction, Ocular; Sulfonamides; Visual Acuity | 2013 |
3 other study(ies) available for phenyl acetate and cp 544326
| Article | Year |
|---|---|
Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Topics: Acetates; Administration, Topical; Animals; Antihypertensive Agents; Aqueous Humor; Biological Availability; Calcium; Ciliary Body; Cornea; Cyclic AMP; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Iris; Macaca fascicularis; Male; Ophthalmic Solutions; Prodrugs; Rabbits; Receptors, Prostaglandin E, EP2 Subtype; Sulfonamides; Tonometry, Ocular | 2011 |
Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma.
Topics: Acetates; Administration, Ophthalmic; Administration, Topical; Animals; Cattle; Cells, Cultured; Dogs; Drug Discovery; Epithelium, Corneal; Glaucoma; Humans; Macaca fascicularis; Male; Receptors, Prostaglandin E, EP2 Subtype; Sulfonamides; Treatment Outcome | 2014 |
Novel Microglia Cell Line Expressing the Human EP2 Receptor.
Topics: Acetates; Animals; Cell Line; Cell Proliferation; Cyclic AMP; Dinoprostone; Humans; Mice; Microglia; Phagocytosis; Receptors, Prostaglandin E, EP2 Subtype; Signal Transduction; Sulfonamides | 2019 |